Bosh sahifaCMXHF • OTCMKTS
add
CSL Ltd
Yopilish kursi
170,75 $
Yillik diapazon
162,94 $ - 210,49 $
Bozor kapitalizatsiyasi
134,29 mlrd AUD
Oʻrtacha hajm
439,00
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
ASX
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | iyn, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 3,37 mlrd | 10,14% |
Joriy xarajat | 1,05 mlrd | 12,78% |
Sof foyda | 370,50 mln | 29,77% |
Sof foyda marjasi | 10,98 | 17,81% |
Har bir ulushga tushum | — | — |
EBITDA | 788,00 mln | 3,01% |
Amaldagi soliq stavkasi | 20,28% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | iyn, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 1,66 mlrd | 7,04% |
Jami aktivlari | 38,02 mlrd | 4,93% |
Jami passivlari | 18,62 mlrd | 1,16% |
Umumiy kapital | 19,40 mlrd | — |
Tarqatilgan aksiyalar | 483,25 mln | — |
Narxi/balansdagi bahosi | 4,75 | — |
Aktivlardan daromad | 4,22% | — |
Kapitaldan daromad | 5,08% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | iyn, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 370,50 mln | 29,77% |
Operatsiyalardan naqd pul | 847,50 mln | 4,57% |
Sarmoyadan naqd pul | -278,50 mln | 22,53% |
Moliyadan naqd pul | -235,00 mln | 43,37% |
Naqd pulning sof oʻzgarishi | 316,00 mln | 1 139,22% |
Boʻsh pul | 348,19 mln | 93,30% |
Haqida
CSL Limited is an Australian multinational specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions. CSL's product areas include blood plasma derivatives, vaccines, antivenom, and cell culture reagents used in various medical and genetic research and manufacturing applications. The company was established in 1916 as Commonwealth Serum Laboratories and was wholly owned by the Australian federal government until its privatisation in 1994. Wikipedia
Tashkil etilgan
1916
Bosh ofis
Sayt
Xodimlar soni
32 698
